Jubilant Life Sciences zoomed 11% to Rs 752.80 at 10:49 IST on BSE after consolidated net profit spurted 1272.3% to Rs 149.03 crore on 7% growth in net sales to Rs 1565.79 crore in Q4 March 2017 over Q4 March 2016.
The result was announced after market hours yesterday, 23 May 2017.Meanwhile, the S&P BSE Sensex was up 145.47 points or 0.48% at 30,510.72.
On the BSE, 2.46 lakh shares were traded on the counter so far as against the average daily volumes of 95,884 shares in the past one quarter. The stock had hit a high of Rs 762.70 and a low of Rs 685.80 so far during the day.
The stock had hit a record high of Rs 879.10 on 14 April 2017 and a 52-week low of Rs 294.20 on 24 June 2016. It had underperformed the market over the past one month till 23 May 2017, sliding 16.01% compared with the Sensex's 3.41% rise. The scrip had also underperformed the market over the past one quarter, declining 4.14% as against the Sensex's 5.1% rise.
The large-cap company has equity capital of Rs 15.93 crore. Face value per share is Rs 1.
Jubilant Life Sciences' Chairman Shyam S Bhartia and Co-Chairman & Managing Director Hari S Bhartia said that the differentiated business model focusing on specialty pharmaceuticals has enabled the company to deliver exceptional results and build a strong base for growth in its pharma business. The company has generated strong operating cash flow which enabled reduction of debt and is expected to deliver better results going forward, they said.
The company's focus is to strengthen the balance sheet, invest in strategic opportunities without increasing debt levels and build strong pipeline of products across specialty, generics and LSI businesses, the duo said.
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients and drug discovery solutions.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
